Target intelligence / Profile preview

Immunoglobulin lambda constant 1 (IGLC1)

Target
IGLC1
Molecular classification
Other (Constant region of immunoglobulin/light chain component)
01

Overview

Immunoglobulin lambda constant 1 (IGLC1) encodes the constant region of the lambda light chain of immunoglobulin molecules, a structural component of antibodies produced by B lymphocytes[1][5]. Immunoglobulin molecules are composed of two heavy and two light chains (either kappa or lambda); the constant region determines the class and effector functions of the light chain in the immune complex[6]. IGLC1 is not a traditional drug target or receptor but is clinically relevant due to its use as a biomarker in diagnosing and monitoring B cell expansions and plasma cell dyscrasias, such as multiple myeloma and AL amyloidosis[5]. Its detection as a monoclonal protein is important for identifying clonal proliferative diseases of B cells. IGLC1 does not have a recognized role as a receptor, enzyme, transporter, or transcription factor, and no approved drugs interact directly with this constant region[5][6].

Other names
Immunoglobulin lambda constant 1IGLC1Ig lambda chain C region MGCIg lambda-1 chain C regionIGLCC1 segmentimmunoglobulin lambda constant 1 (Mcg marker)immunoglobulin lambda constant region 1 (Mcg marker)
02

Biological functions

Immune response (constituent of antibodies)Antigen binding (via immunoglobulin complex)
03

Disease associations

Cancer (certain lymphomas, multiple myeloma—dysregulation or monoclonal expansion of immunoglobulin lambda light chains)Other (immune system disorders, e.g. paraproteinemias, amyloidosis)
04

Safety considerations

Overexpression or monoclonality associated with pathological states (e.g., multiple myeloma, AL amyloidosis), but not an independent drug target
05

Biomarkers

Monoclonal lambda light chain detection in serum/urine (marker for multiple myeloma, B cell malignancies)Serum free light chain measurement (for plasma cell dyscrasias)

Beyond the preview

Go deeper on Immunoglobulin lambda constant 1 (IGLC1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin lambda constant 1 (IGLC1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call